Allarity Therapeutics Statistics
Share Statistics
Allarity Therapeutics has 17.08M
shares outstanding. The number of shares has increased by -82.67%
in one year.
| Shares Outstanding | 17.08M |
| Shares Change (YoY) | -82.67% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 19.14% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 7,903 |
| FTD / Avg. Volume | 0.42% |
Short Selling Information
The latest short interest is 1.45M, so 8.53% of the outstanding
shares have been sold short.
| Short Interest | 1.45M |
| Short % of Shares Out | 8.53% |
| Short % of Float | 8.53% |
| Short Ratio (days to cover) | 1.14 |
Valuation Ratios
The PE ratio is -0.08 and the forward
PE ratio is -0.02.
Allarity Therapeutics's PEG ratio is
0.
| PE Ratio | -0.08 |
| Forward PE | -0.02 |
| PS Ratio | 0 |
| Forward PS | 0.2 |
| PB Ratio | 0.16 |
| P/FCF Ratio | -0.1 |
| PEG Ratio | 0 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Allarity Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.06,
with a Debt / Equity ratio of 0.11.
| Current Ratio | 2.06 |
| Quick Ratio | 2.06 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | -0.05 |
| Debt / FCF | -0.08 |
| Interest Coverage | 41.72 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-4,085,833.33 |
| Employee Count | 6 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -381K |
| Effective Tax Rate | 1.53% |
Stock Price Statistics
The stock price has increased by -95.27% in the
last 52 weeks. The beta is -0.15, so Allarity Therapeutics's
price volatility has been lower than the market average.
| Beta | -0.15 |
| 52-Week Price Change | -95.27% |
| 50-Day Moving Average | 0.96 |
| 200-Day Moving Average | 1.92 |
| Relative Strength Index (RSI) | 54.54 |
| Average Volume (20 Days) | 1,864,560 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -27.24M |
| Net Income | -24.52M |
| EBITDA | -27.24M |
| EBIT | -25.55M |
| Earnings Per Share (EPS) | 0 |
Full Income StatementBalance Sheet
The company has 19.53M in cash and 1.35M in
debt, giving a net cash position of 18.18M.
| Cash & Cash Equivalents | 19.53M |
| Total Debt | 1.35M |
| Net Cash | 18.18M |
| Retained Earnings | -118.97M |
| Total Assets | 22.65M |
| Working Capital | 11.5M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -17.35M
and capital expenditures -298K, giving a free cash flow of -17.65M.
| Operating Cash Flow | -17.35M |
| Capital Expenditures | -298K |
| Free Cash Flow | -17.65M |
| FCF Per Share | -11.2 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
